Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress was held in St. Gallen, Switzerland, from the 27–29th September.

Highlights include updates on the use of checkpoint inhibitors and antibody therapies for cutaneous T-cell lymphoma, the future outlook for ECP, convenient topical agents, and updates on PROCLIPI studies.

EORTC CLTF 2018

27–29 September 2018 | St. Gallen, Switzerland

EORTC CLTF 2018

27–29 September 2018 | St. Gallen, Switzerland

The European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress was held in St. Gallen, Switzerland, from the 27–29th September.

Highlights include updates on the use of checkpoint inhibitors and antibody therapies for cutaneous T-cell lymphoma, the future outlook for ECP, convenient topical agents, and updates on PROCLIPI studies.

CD47-blocking checkpoint inhibitor TTI-621 shows promising results for cutaneous T-cell lymphomas 2:15
CD47-blocking checkpoint inhibitor TTI-621 shows promising results for cutaneous T-cell lymphomas
Christiane Querfeld • 27 Sep 2018
Update on CAR T-cell therapy at the City of Hope 1:22
Update on CAR T-cell therapy at the City of Hope
Steven Rosen • 27 Sep 2018
Insight into CTCL intratumor heterogeneity may inform disease management 1:25
Insight into CTCL intratumor heterogeneity may inform disease management
Robert Gniadecki • 27 Sep 2018
Management & research for CTCL at the City of Hope 2:09
Management & research for CTCL at the City of Hope
Steven Rosen • 27 Sep 2018
High-throughput sequencing to inform mycosis fungoides management 1:13
High-throughput sequencing to inform mycosis fungoides management
Robert Gniadecki • 27 Sep 2018
How will the treatment landscape for CTCL change in the coming years? 2:17
How will the treatment landscape for CTCL change in the coming years?
Chalid Assaf • 27 Sep 2018
ECP experience in Canada: prospects and challenges 1:54
ECP experience in Canada: prospects and challenges
Robert Gniadecki • 27 Sep 2018
New molecular targets for cutaneous T-cell lymphoma therapy 2:03
New molecular targets for cutaneous T-cell lymphoma therapy
Chalid Assaf • 27 Sep 2018
Cutaneous lymphoma treatment in Spain 1:01
Cutaneous lymphoma treatment in Spain
Pablo Ortiz Romero • 27 Sep 2018
Mogamulizumab: an exciting antibody for autoimmunity 0:58
Mogamulizumab: an exciting antibody for autoimmunity
Martine Bagot • 27 Sep 2018
Targeting PLCG1: a calcineurin inhibitor for early mycosis fungoides 1:20
Targeting PLCG1: a calcineurin inhibitor for early mycosis fungoides
Pablo Ortiz Romero • 27 Sep 2018
Future directions for checkpoint inhibitors in cutaneous lymphoma treatment 1:35
Future directions for checkpoint inhibitors in cutaneous lymphoma treatment
Michael Khodadoust • 27 Sep 2018
Pembrolizumab trial shows promising responses in cutaneous lymphoma 1:40
Pembrolizumab trial shows promising responses in cutaneous lymphoma
Michael Khodadoust • 27 Sep 2018
First-in-human study of IPH4102 for relapsed cutaneous T-cell lymphoma 1:28
First-in-human study of IPH4102 for relapsed cutaneous T-cell lymphoma
Martine Bagot • 27 Sep 2018
Quality of life in cutaneous lymphoma patients: patient-reported outcomes 1:29
Quality of life in cutaneous lymphoma patients: patient-reported outcomes
Pablo Ortiz Romero • 27 Sep 2018
Chlormethine gel: opinion on potential approval and usage in Europe 0:37
Chlormethine gel: opinion on potential approval and usage in Europe
Martine Bagot • 27 Sep 2018

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals